Actively Recruiting
A Trial to Study if REGN17372 in Combination With Linvoseltamab is Tolerable for Adult Participants With Relapsed/Refractory Multiple Myeloma
Led by Regeneron Pharmaceuticals · Updated on 2026-04-15
150
Participants Needed
2
Research Sites
392 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study is researching a drug called REGN17372 used with another drug called linvoseltamab (each individually called "study drug" or "study drugs" when combined) in participants with relapsed (when a tumor comes back) or refractory (when a tumor does not respond to treatment) multiple myeloma. This study is the first time REGN17372 will be given to humans. The aim of the study is to understand if REGN17372 can be given safely with linvoseltamab, and if so, what dosing regimen should be used for this treatment combination, in comparison with linvoseltamab alone. The study is looking at: * What side effects may happen from taking REGN17372 with linvoseltamab * How well REGN17372 and linvoseltamab, or linvoseltamab alone, work in treating multiple myeloma * What is the best dose of REGN17372 when given with linvoseltamab * How much study drug(s) are in the blood at different times * Whether the body makes antibodies against the study drugs (which could make the study drugs less effective or could lead to side effects) * If and how REGN17372 and linvoseltamab affect the overall quality of life, daily activities, symptoms and treatment side effects based on participant own feedback (Phase 2)
CONDITIONS
Official Title
A Trial to Study if REGN17372 in Combination With Linvoseltamab is Tolerable for Adult Participants With Relapsed/Refractory Multiple Myeloma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults with relapsed or refractory multiple myeloma who have tried at least 3 prior treatment lines or are not candidates for other therapies providing meaningful benefit
- ECOG performance status score of 0 or 1
- Measurable multiple myeloma disease for response evaluation
- Adequate blood, heart, liver, and kidney function as defined by the study protocol
You will not qualify if you...
- Participants with non-secretory multiple myeloma, active plasma cell leukemia, known amyloidosis, Waldenstr�f6m macroglobulinemia, or POEMS syndrome
- Participants with known brain lesions or central nervous system involvement from multiple myeloma
- History of progressive multifocal leukoencephalopathy (PML), neurocognitive conditions, CNS movement disorders, or seizures within 12 months before screening
- Prior treatment with GPRC5D-directed immunotherapies or BCMAxCD3 bispecific antibodies as specified in the protocol
- Other protocol-defined exclusion criteria may apply
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Prince of Wales Hospital
Randwick, New South Wales, Australia, 2031
Actively Recruiting
2
Illawarra Cancer care centre, Wollongong Hospital
Wollongong, New South Wales, Australia, 2500
Actively Recruiting
Research Team
C
Clinical Trials Administrator
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here